Home Interventional Oncology DC Bead LUMI™ About About DC Bead LUMI™

VISION

With DC Bead LUMI™, you are empowered to see the location of the beads during and after LUMI-TACE

"This case was impressive because of the clear visualisation of the tumour and the embolised vessels on the post-embolisation non-contrast CBCT, in addition to the complete response of the treated lesions."

Early experience user feedback
dc bead lumi
dc bead lumi

DC Bead LUMI™ visible in tumour-feeding vessels on fluoroscopy during procedure after clearance of contrast

dc bead lumi

CBCT 10 mins post procedure confirms coverage of tumour

dc bead lum

DC Bead LUMI™ remain visible at 4-week follow-up on non contrast-enhanced CT. MRI confirms complete response of tumour (mRECIST)

PRECISION

DC Bead LUMI™ are designed to offer a more precise and controlled procedure than current techniques

"The radiopacity allows for accurate needle placement and full lesion ablation. With standard DC Bead™, the lesion cannot be seen on non-contrast CT and there is a possibility that the lesion may not be fully ablated."

Early experience user feedback
dc bead lumi
dc bead lumi

CT immediately post embolisation

dc bead lumi

Four days after embolisation, <br> DC Bead LUMI™ are visible <br> on non-contrast CT, allowing <br> for accurate needle placement

dc bead lum

Non-contrast CT after microwave ablation demonstrates completeness of treatment

assurance

DC Bead LUMI™ offer the best opportunity to individualise your patients’ treatment

"The real-time visualisation of the DC Bead LUMI™, and not a surrogate of contrast and beads, gave me confidence to see exactly where my therapy was being delivered."

Early experience user feedback
dc bead lumi
dc bead lumi
Single-shot fluoroscopy during the procedure
dc bead lumi
CBCT 10 mins post embolisation with DC Bead LUMI™
dc bead lum
DC Bead LUMI™ remain visible on non-contrast CT at 6-week follow-up. Complete response confirmed on MRI

dc_bead_lumi_aboutpng.png


Description

  • DC Bead LUMI™ are the first-ever radiopaque drug-eluting beads.They have been developed on the same technology platform and to the same high standard as DC Bead™

Presentation and Sizing

  • DC Bead LUMI™ are available in the same presentation as DC Bead™ (2ml of beads per vial) in two calibrated size ranges. Supplied with Vialok™ vented transfer device
Size 70–150 μm 100–300 μm
Label Colour™
70–150 μm		 Black Yellow
Volume of Beads™
100–300 μm		 2ml 2ml
Product Code™
100–300 μm		 R02D001 R02D103


DC Bead LUMI™ are:

  • Inherently and consistently radiopaque with iodine evenly distributed throughout
  • Visible under all standard X-ray imaging modalities
  • Visible as they accumulate in vessels and contrast clears
  • Visible in follow-up scans due to long-lasting radiopacity
  • Approved for loading with doxorubicin and irinotecan

DC Bead LUMI™ provide increased control and optimise patient treatment strategies because they:

  • Enable real-time adjustments during procedure to guide precise delivery of beads into the tumour Enhance determination of embolisation endpoint
  • Assist in discovering regions of under treatment
  • Allow for the precise evaluation and confident reporting of the completeness of tumour treatment
  • Help inform future treatment planning

Administration

  • DC Bead LUMI™ are delivered in commonly used contrast agents without dilution and via routinely used microcatheters

Radiopacity

  • DC Bead LUMI™ are visible under all standard X-ray modalities including computed tomography [CT], cone-beam computed tomography [CBCT] and fluoroscopy
  • DC Bead LUMI™ may overcome some of the image limitations associated with current conventional TACE/DEB-TACE procedures
  • Real-time visualisation of bead delivery may allow for better control of bead location and endpoint determination
  • Potential to use follow-up imaging for tumour “marking” and to confirm location of beads, success of embolisation procedure and planning for future treatment


Duran R et al. Theranostics 2016; 6(1): 28-39
CT: Computed tomography

Drug Loading and Elution

  • Approved for loading with doxorubicin and irinotecan
  • In-vitro testing confirms that the controlled and sustained elution profiles of drug from DC Bead LUMI™are comparable to those achieved with DC Bead™
    • Elution of doxorubicin and irinotecan falls within the same window as DC Bead™1
    • Under the same conditions, both DC Bead LUMI™ and DC Bead™ achieve complete elution of doxorubicin and irinotecan1,2
  • DC Bead LUMI™ do not reduce in diameter when loaded with drug
 
  1. Swaine TS et al. Poster presentation APS meeting, Nottingham, UK. September 2015.
  2. Data on file (FAR-ES-0121) at Biocompatibles UK

 

About

About BTG

About Interventional Oncology

Interventional Oncology Products

Imagine where we can go.

Important Safety Information:


INDICATION:

DC Bead LUMI™ can be used as an embolic agent with or without delivery of doxorubicin or irinotecan. Unloaded DC Bead LUMI™ are intended to be used for the embolisation of non-malignant hypervascular tumours and arteriovenous malformations (AVMs).

For the use in malignant indications:

  • DC Bead LUMI™ are primarily intended as an embolic agent for the local treatment of malignant hypervascularised tumour(s) in the liver.
  • DC Bead LUMI™ are compatible with doxorubicin for the local treatment of tumours in patients with hepatocellular carcinoma (HCC). Doxorubicin can be loaded prior to embolisation and then as a secondary action, the beads will elute a local, controlled and sustained dose to the tumour after embolisation.
  • DC Bead LUMI™ are also intended to embolise the vessels supplying malignant colorectal cancer metastasised to the liver (mCRC).
  • DC Bead LUMI™ are compatible with irinotecan which can be loaded prior to embolisation and then as a secondary action, the beads will elute a local, controlled and sustained dose to the liver metastases from colorectal cancer after embolisation.

WARNING:

It is the doctor’s responsibility to give due consideration to the details in the drug product marketing authorisation in deciding which drug (either doxorubicin or irinotecan) to load DC Bead LUMI™ with and whether loading with that drug is appropriate for the patient under his/her care .The relevant Summary of Product Characteristics (SmPC) must be consulted. The type and dose of drug should also be assessed according to the individual patient’s clinical circumstances.

DC Bead and DC Bead LUMI are trademarks and/or registered trademarks of Biocompatibles UK Limited, a BTG International group company. Imagine where we can go, BTG and the BTG roundel logo are trademarks of BTG International Ltd. BTG and the BTG roundel logo are registered trademarks in the USA, the European Union and certain other territories. © 2017 Biocompatibles UK Ltd. EM-LUM-2017-0025. EMEA. Date of preparation January 2017.